 |
Previous Article | Next Article 
The Journal of Neuroscience, June 15, 1999, 19(12):4796-4803
Presynaptic µ and Opioid Receptor Modulation of
GABAA IPSCs in the Rat Globus Pallidus In
Vitro
Ian M.
Stanford and
Alison J.
Cooper
The Department of Pharmacology, The Division of Neuroscience, The
Medical School, The University of Birmingham, Edgbaston, Birmingham B15
2TT, United Kingdom
 |
ABSTRACT |
The role of enkephalin and the opioid receptors in modulating GABA
release within the rat globus pallidus (GP) was investigated using
whole-cell patch recordings made from visually identified neurons. Two
major GP neuronal subtypes were classified on the basis of intrinsic
membrane properties, action potential characteristics, the presence of
the anomalous inward rectifier (Ih),
and anode break depolarizations.
The µ opioid receptor agonist
[D-Ala2-N-Me-Phe4-Glycol5]-enkephalin
(DAMGO) (1 µM) reduced GABAA
receptor-mediated IPSCs evoked by stimulation within the
striatum. DAMGO also increased paired-pulse facilitation, indicative of
presynaptic µ opioid receptor modulation of striatopallidal input. In
contrast, the opioid agonist
D-Pen-[D-Pen2,5]-enkephalin
(DPDPE) (1 µM) was without effect.
IPSCs evoked by stimulation within the GP were depressed by application
of [methionine 5']-enkephalin (met-enkephalin) (30 µM).
Met-enkephalin also reduced the frequency, but not the amplitude, of
miniature IPSCs (mIPSCs) and increased paired-pulse facilitation of
evoked IPSCs, indicative of a presynaptic action. Both DAMGO and DPDPE
reduced evoked IPSCs and the frequency, but not amplitude, of
mIPSCs. However, spontaneous action potential-driven IPSCs were
reduced in frequency by met-enkephalin and DAMGO, whereas DPDPE was
without effect.
Overall, these results indicate that presynaptic µ opioid receptors
are located on striatopallidal terminals and pallidopallidal terminals
of spontaneously firing GP neurons, whereas presynaptic opioid
receptors are preferentially located on terminals of quiescent GP
cells. Enkephalin, acting at both of these receptor subtypes, serves to
reduce GABA release in the GP and may therefore act as an adaptive
mechanism, maintaining the inhibitory function of the GP in basal
ganglia circuitry.
Key words:
whole-cell patch clamp; brain slices; basal ganglia; enkephalin; GABAA IPSC; opioid receptors
 |
INTRODUCTION |
The external segment of the primate
globus pallidus (GPe), equivalent to the rat globus pallidus (GP),
occupies a critical position in basal ganglia (BG) circuitry (Alexander
and Crutcher, 1990 ; Parent, 1990 ). It receives a major GABA-enkephalin
projection from a discrete population of medium spiny striatal neurons
(Wilson and Phelan, 1982 ; Gerfen and Young, 1988 ; Hazrati and Parent, 1992 ; Parent and Hazrati, 1995 ), in turn sending projections to the
subthalamic nucleus (STN) (Smith et al., 1990 ; Parent and Hazrati,
1995 ), internal segment of the globus pallidus (entopeduncular nucleus in rodents) (Kincaid et al., 1991 ; Bolam and Smith, 1992 ), substantia nigra pars reticulata (Smith and Bolam, 1989 ),
reticular thalamic nucleus (Cornwall et al., 1990 ; Hazrati and Parent,
1991 ; Gandia et al., 1993 ), and striatum (Bevan et al., 1998 ).
Although the prevailing model of BG function (DeLong, 1990 ) has
recently received criticism from several sources (Parent and Hazrati,
1995 ; Chesselet and Delfs, 1996 ; Obeso et al., 1997 ), it remains a
useful tool to explain many disorders of movement. In Parkinson's
disease, dopamine depletion is thought to lead to an increase in the
activity of the indirect GABA-enkephalin striatopallidal pathway.
Indeed, there is evidence for increased enkephalin gene expression in
the striatum (Augood et al., 1989 ; Gerfen et al., 1990 ; Frayne et al.,
1991 ) and increased enkephalin immunoreactivity in the GPe (Lavoie et
al., 1991 ) in animal models of parkinsonism. In keeping with the
proposal that the GABA striatopallidal pathway is overactive after
dopamine depletion, injection of GABAA receptor antagonists
directly into the GP has been shown to increase locomotor score in
parkinsonian animals (Maneuf et al., 1994 ). Furthermore, direct
injection of GABAA antagonists and µ and opioid
receptor agonists into the ventral pallidum (the limbic homolog
of the GP) of normal animals also promotes locomotor activity (Austin
and Kalivas, 1990 ; Napier, 1992 ). The effects of opioid receptor
agonists have been attributed to the presynaptic inhibition of GABA
release from striatopallidal terminals (Dewar et al., 1987 ; Maneuf et
al., 1994 ). Indeed, anatomical studies have provided evidence that µ opioid receptors are located on striatopallidal presynaptic terminals
(Abou Khalil et al., 1984 ). However, more recently, ligand binding,
mRNA, and immunohistochemical studies have indicated the presence of
both presynaptic and postsynaptic µ and opioid receptors
within the GP (Delfs et al., 1994 ; Mansour et al., 1994 , 1995 ; Bausch
et al., 1995 ; Peckys and Landwehrmeyer, 1999 ).
Two major types of GP neuron have been determined by in vivo
and in vitro electrophysiological, morphological, and
neurochemical experiments (DeLong, 1971 ; Hontanilla et al., 1994 ; Kita
and Kitai, 1994 ; Nambu and Llinás, 1994 , 1997 ). These neurons
appear to display widespread intrinsic axon collaterals (Kita and
Kitai, 1994 ; Nambu and Llinás, 1997 ). Therefore, the presence of
presynaptic opioid receptors within the GP may reflect receptor
expression on collateral terminals, as well as striatopallidal terminals.
The aim of this study was therefore to determine (1) the presence and
function of µ and opioid receptors on pallidal and striatal
terminals, (2) the presence of functional postsynaptic µ and opioid receptors, and (3) whether there is a correlation between GP
neuronal heterogeneity and differential opioid receptor activity.
 |
MATERIALS AND METHODS |
Whole-cell patch-clamp recordings were made from single GP
neurons within 300-µm-thick slices obtained from 80-120 gm male Wistar rats. Animals were first anesthetized with fluorothane and
killed by cervical dislocation. The brain was quickly removed and placed in ice-cold artificial CSF (aCSF) containing (in
mM): choline chloride 126, KCl 2.5, NaH2PO4 1.2, MgCl2 1.3, MgSO4 8, and glucose 10, buffered to pH 7.4 with
NaHCO3 26. Slices were cut in either coronal or
parasagittal plane using a DTK-1000 Microslicer (Dosaka, Japan). Slices
were then transferred to a holding chamber or recording chamber at
32-34°C and perfused continuously at 2-3 ml/min with aCSF
containing (in mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, MgCl2 1.3, CaCl2 2.4, and glucose 10, buffered to pH 7.4 with
NaHCO3 26, saturated with 95% O2-5%
CO2.
Whole-cell recordings from GP neurons were made using borosilicate
glass pipettes of 3-6 M resistance containing (in mM): K-gluconate 125, NaCl 10, CaCl2 1, MgCl2 2, BAPTA 10, HEPES 10, GTP 0.3, Mg-ATP 2, and biocytin 5, adjusted to pH
7.25 with KOH. Individual neurons were visualized (40× water immersion
objective) using a differential interference contrast infrared
microscopy (BX 501; Olympus Optical, Tokyo, Japan) with CCD
camera (KP-M1; Hitachi, Tokyo, Japan) and contrast enhancement system
(ADV-2; Brian Reece Scientific, Berkshire, UK). Recording pipettes were advanced while under positive pressure toward individual cells in the
slice. On contact, tight seals, in the order of 10-20 G , were made
by applying negative pressure. The membrane patch was then ruptured by
suction, and membrane current and potential was monitored using an
Axopatch 200B patch-clamp amplifier (Axon Instruments, Foster City,
CA). Whole-cell access resistances were in the range of 7-20 M
before electrical compensation by 65-80%. Access resistances, after
electrical compensation, were initially determined in current-clamp mode and continuously monitored in voltage clamp by measuring the size
of the capacitance transient in response to a 10 mV hyperpolarizing step (Stuart et al., 1993 ). The access resistance was checked intermittently in current clamp, and experiments were abandoned if
changes >20% were encountered. All current-clamp recordings were made
in Axopatch 200B fast mode, and membrane potentials were corrected with
respect to the null potential measured at the end of recording. No
corrections have been made for the liquid junction potentials,
estimated to be +8 mV.
Synaptic events were evoked by focal bipolar single shock stimulation
(0.5 msec, 0.1-3 mA) at 15 sec intervals using a constant current
stimulation unit (DS2A; Digitimer, Hertfordshire, UK). Voltage steps
were generated using pCLAMP software version 6.03 (Axon Instruments),
and the resulting membrane currents and those resulting from synaptic
activation were filtered at 2 kHz and stored on disk and digital analog
tape recorder for subsequent analysis and display on a chart recorder
(Gould Easygraph; Gould Instruments, Hainault, UK). To record
mIPSCs, the K-gluconate in the recording pipette was replaced
with KCl. In doing this, the theoretical chloride reversal potential
moved from 61 to +1 mV. mIPSCs were then recorded in tetrodotoxin
(TTX) (1 µM) at a potential of 80 mV. Data were
collected over 2 min periods, acquired using FETCHEX (Axon
Instruments), and analyzed using Minianalysis software (Jaejin
Software, Leonia, NJ).
Drugs were applied to the superfusate by exchanging the aCSF for one
differing only by the addition of a known concentration of drug, with
the exchange beginning after a dead time of ~20 sec. Drugs used were
as follows: 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX),
DL-2-amino-5-phosphonopentanoic acid
(DL-AP-5), bicuculline methiodide, picrotoxin, and
ICI 174,864 (all from SEMAT); [methionine 5']-enkephalin]
(met-enkephalin),
[D-Ala2-N-Me-Phe4-Glycol5]-enkephalin
(DAMGO),
D-Pen-[D-Pen2,5]-enkephalin
(DPDPE),
D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), and TTX (all from Sigma, Poole, UK).
All numerical data are expressed as mean and SE unless otherwise
stated. Differences in IPSC data were analyzed for statistical significance using the paired Student's t test, and
significant differences in the cumulative frequency and amplitude of
spontaneous IPSCs (sIPSCs) and mIPSCs were analyzed using the
Kolmogorov-Smirnov two-sample test (Jaejin Software).
 |
RESULTS |
Characterization of globus pallidus neurons
GP neurons were characterized by their electrophysiological
properties and classified into two major groups. These two classes of
neuron showed similar but not identical properties to the type I and II
neurons described previously by Nambu and Llinás (1994) . Type I
neurons were spontaneously active, firing irregular action potentials
at 13 ± 3.1 Hz (n = 19) at a resting membrane
potential of 52.4 ± 7.8 mV (measured at I = 0).
The input resistance of these cells was 349 ± 35.9 M
(n = 19), and action potential duration (taken as the
time between the point of initiation of the maximum rate of
depolarization and the equipotential point during spike repolarization)
was 0.82 ± 0.1 msec (n = 19), followed by a
short-lasting afterhyperpolarization (AHP) of amplitude
29.2 ± 2 mV (n = 19) (Fig.
1A).

View larger version (22K):
[in this window]
[in a new window]
|
Figure 1.
Characterization of two GP neuronal subtypes.
A, i, Superimposed voltage responses from
a type I neuron in response to 300 msec hyperpolarizing currents steps
(25 pA increments every 5 sec) from a resting membrane potential of
50.8 mV. This neuron was spontaneously active at 10 Hz.
ii, Typical action potential from a type I neuron of
0.78 msec duration and short-lasting AHP of 29 mV amplitude.
B, i, Voltage traces from a type II
neuron in response to 300 msec current steps (in 25 pA increments every
5 sec) from resting membrane potential of 67 mV. Hyperpolarizing
steps elicited time-dependent inward rectification of membrane
potential. On removal of the step, there was an anodal break
depolarization accompanied by action potential firing.
ii, Representative action potential from a type II GP
neuron of 0.95 msec duration and a long-lasting AHP of amplitude
27 mV.
|
|
Type II neurons were identified by the presence of the time- and
voltage-dependent inward rectification of membrane potential evoked by
hyperpolarizing steps of 300 msec duration and anodal break rebound
depolarizations. These rebound depolarizations were often accompanied
by action potential firing (Fig. 1B). Type II neurons
were either quiescent (22 of 38 cells) or fired regular spontaneous
action potentials at a rate of 7.5 ± 1.6 Hz (16 of 38) at a
resting membrane potential of 53.4 ± 2.5 mV. The input resistance of these cells was 646.1 ± 41.8 M
(n = 38; significantly different from type I cells,
p < 0.01), and the action potential duration was
1.1 ± 0.1 msec (n = 38; significantly different
from type I cells, p < 0.01), followed by a prolonged
AHP of amplitude 29.3 ± 6.6 mV (n = 38).
Evoked GABA A receptor IPSCs
At a holding potential of 50 mV, single shock electrical
stimulation evoked a fast inward synaptic current, followed by a slower
outward current. These currents appeared to be independent of slice
orientation and stimulation location. The inward current was blocked by
the glutamate antagonists CNQX (10 µM) and
DL-AP-5 (100 µM) (Fig.
2A), whereas the slower
outward current was blocked by bicuculline (10 µM;
n = 4) (Fig. 2B) or picrotoxin (50 µM; n = 2) (data not shown). The outward
current reversed polarity at approximately 70 mV (Fig.
2C), close to the theoretical chloride equilibrium potential
(ECl of 61 mV) and was therefore considered to
be a GABAA receptor-mediated IPSC.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 2.
Synaptic currents evoked by local stimulation.
A, At a holding potential of 50 mV, single shock
bipolar electrical stimulation evoked a fast inward current that was
blocked by CNQX (10 µM) and DL-AP-5 (100 µM) and a slower outward current. Each
trace is preceded by a 10 mV hyperpolarizing step of 10 msec duration to monitor input conductance and changes in access
resistance. B, Time course from a single experiment
showing the reversible block of outward synaptic potential by the
GABAA antagonist bicuculline (10 µM) applied
to the superfusion medium for the period indicated by the bar. Each
point represents the average of four traces evoked every 15 sec.
C, The outward current reversed polarity at 69 mV,
close to ECl.
|
|
µ Opioid receptors on striatopallidal terminals
The opioid receptor modulation of GABA release from
striatopallidal terminals was studied by stimulation within the
striatum (in parasagittal slices) in the presence of CNQX (10 µM) and DL-AP-5 (100 µM).
Obtaining robust synaptic responses using this orientation of slice and
stimulation location proved technically difficult, possibly because
of the topographic nature of striatopallidal connections (Wilson
and Phelan, 1982 ). However, application of the µ opioid receptor
agonist DAMGO (1 µM) reduced the IPSCs by 53 ± 6%
(n = 7) (Fig.
3A), whereas the opioid
receptor agonist DPDPE was without effect (n = 5) (Fig.
3B). In each of these five cells, application of DAMGO (1 µM) significantly reduced the evoked IPSC. The action of
DAMGO appeared to be independent of cell phenotype, inhibiting IPSCs in
three type I and four type II cells.

View larger version (21K):
[in this window]
[in a new window]
|
Figure 3.
Presynaptic depression of evoked striatopallidal
IPSCs by µ opioid receptor activation. A, Time course
showing the effect of the µ opioid receptor agonist DAMGO (1 µM) on the normalized IPSC amplitude evoked by
stimulation of striatum in parasagittal slices in the presence of CNQX
(10 µM) and DL-AP-5 (100 µM).
DAMGO reduces the IPSC by 53 ± 6% (n = 7).
B, Time course showing the effect of the opioid
receptor agonist DPDPE (1 µM) on the normalized IPSC
amplitude evoked by stimulation of the striatum in parasagittal slices
in the presence of CNQX (10 µM) and DL-AP-5
(100 µM). DPDPE has no significant effect on the evoked
IPSC (n = 5). However, the IPSC evoked in each of
these five cells was inhibited by DAMGO (1 µM).
C, Paired IPSCs recorded from the same cell in response
to the same stimulation at an interval of 50 msec in control
(i) and DAMGO (1 µM)
(ii). iii, The pair of IPSCs recorded in
the presence of DAMGO have been scaled so that the conditioning (first)
responses with and without drug are of similar amplitude. The ratio of
the test (second) response in DAMGO has increased, indicative of a
presynaptic site of action. Paired IPSCs recorded in the presence of
the µ opioid receptor antagonist CTOP (1 µM)
(iv) and CTOP plus DAMGO (1 µM)
(v), and ratio (vi). In the
presence of CTOP, there was no depression of the conditioning IPSC by
DAMGO and no change in the paired-pulse ratio. Currents resulting from
a 10 mV hyperpolarizing step precede all IPSC pairs.
|
|
A paired-pulse protocol was used to show µ opioid receptor modulation
of the striatal evoked IPSCs was presynaptic (Davies et al., 1990 ;
Travagli and Williams, 1996 ). IPSCs were evoked by single shock
electrical stimulation of equal strength and duration at an interval of
30 msec. Application of DAMGO (1 µM) reduced the
amplitude of the conditioning (first) IPSC and test (second) IPSC but
significantly increased the paired-pulse facilitation (21 ± 10.7%; p < 0.05; n = 4) (Fig.
3C). This effect was totally abolished by preincubation (20 min) with the µ opioid receptor antagonist CTOP (1 µM;
n = 3) (Fig. 3C).
Met-enkephalin reduces the IPSCs evoked by stimulation within the
GP via a presynaptic mechanism
Using coronal slices, electrical stimulation within the GP,
300-900 µm away from the recording site, evoked IPSCs that were reduced reversibly by bath application of met-enkephalin (30 µM; 53.4 ± 5.1%; n = 11) (Fig.
4A). To determine the
locus of such modulation, the action of met-enkephalin on the
paired-pulse ratio and the frequency and amplitude of action potential
independent mIPSCs was studied.

View larger version (17K):
[in this window]
[in a new window]
|
Figure 4.
Enkephalin reduces GABAA IPSCs. IPSCs
recorded at a holding potential of 50 mV in the presence of CNQX (10 µM) and DL-AP-5 (100 µM).
A, i, IPSCs (mean of 4 evoked every 15 sec) before (a) and during
(b) the application of met-enkephalin (30 µM) and after wash (c).
A, ii, Time course showing the effect of
bath application of met-enkephalin (30 µM) on normalized
IPSC amplitude. B, Paired IPSCs recorded from a type II
GP neuron in control (i) and met-enkephalin (10 µM) (ii). iii, The pair of
IPSCs recorded in the presence of met-enkephalin has been scaled so
that the conditioning (first) responses with and without drug are of similar amplitude. The increase in
ratio of the test (second) response is indicative of a presynaptic site
of action of met-enkephalin. C, mIPSCs were recorded
from chloride loaded cells (ECl, +1
mV) in the presence of TTX (1 µM), CNQX (10 µM), and DL-AP-5 (100 µM) at a
holding potential of 80 mV. mIPSCs were collected over a period of
120 sec. The same time frame was taken 3 min after drug application.
i, Control mIPSCs and those recorded after application
of met-enkephalin (30 µM). ii, Cumulative
frequency and amplitude distributions (derived from 120 sec of data)
before and after met-enkephalin. Met-enkephalin reduced the frequency
of mIPSCs (p < 0.01) but not their
amplitude.
|
|
Met-enkephalin (10-30 µM) reduced the amplitude of the
conditioning (first) and test (second) IPSC but increased the
paired-pulse ratio (20.2 ± 10.8%; p < 0.05;
n = 5) (Fig. 4B).
mIPSCs were recorded in chloride loaded cells at a holding potential of
80 mV in the presence of TTX (1 µM), CNQX (10 µM), and DL-AP-5 (100 µM) (Fig.
4C). IPSCs were considered "minis" after abolition by
TTX (1 µM) of electrically evoked synaptic currents and
action potentials during depolarizing current steps. Bath application
of met-enkephalin (30 µM) significantly reduced the
frequency of mIPSCs in five of seven cells (p < 0.05), whereas the amplitude of mIPSCs was unaffected by met-enkephalin
in six of seven cells (Fig. 4C).
These results suggest that met-enkephalin acts via presynaptic opioid
receptors leading to a reduction of GABA release within the GP.
Consistent with this interpretation, changes in holding current after
met-enkephalin application were rarely observed. Only 4 of 19 cells
exhibited a detectable outward current, which was 27.5 ± 11.1 pA
in amplitude (data from three type I and one type II neurons).
µ and opioid receptor agonists reduce IPSCs evoked by
stimulation in the GP and mIPSCs
The opioid receptor agonist DPDPE (1 µM) reduced
the amplitude of the IPSC evoked by stimulation in the GP (in coronal
slices) by 49.9 ± 6.7% (n = 8). The depression
of the evoked IPSC by the µ opioid receptor agonist DAMGO (1 µM) was more variable, ranging from 0 to 60% (mean,
29 ± 9.8%; n = 6) (Fig.
5). The presynaptic action of both
agonists was confirmed by analysis of mIPSCs. Bath application of DPDPE
(1 µM) significantly reduced the frequency of mIPSCs
(p < 0.05) in three of four cells (one type I
and two type II neurons), whereas the amplitude of mIPSCs was not
significantly reduced in three of four cells (Fig. 5B).
Application of DAMGO (1 µM) significantly reduced the
frequency of mIPSCs (p < 0.05) in five of seven
cells (two I and three II type cells), although the amplitude of events
was not significantly reduced in six of seven cells (Fig.
5B). These results confirm the presence of both presynaptic µ and receptors on terminals of both type I and II GP neurons,
regulating GABA release within the GP.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 5.
The agonist DPDPE rather than the µ opioid
agonist DAMGO preferentially reduced IPSCs evoked by stimulation within
the GP. A, Time course showing the effect of the opioid receptor agonist DPDPE (1 µM)
(i) and the µ opioid receptor agonist DAMGO (1 µM) (ii) on normalized IPSC amplitude
evoked by stimulation within the GP. DPDPE reduced the IPSC by
49.9 ± 6.7% (n = 8), but DAMGO only reduced
the IPSC by 29 ± 9.8% (n = 6).
B, Cumulative frequency (i) and
amplitude (ii) distributions of mIPSCs before and after
the application of DPDPE and DAMGO from two representative experiments.
Both agonists reduced the frequency of the events
(p < 0.01) without change in
amplitude.
|
|
Spontaneous IPSCs are reduced by µ but not opioid
receptor agonists
In the presence of CNQX (10 µM) and
DL-AP-5 (100 µM), 78% of GP neurons
displayed outward sIPSCs (in nonchloride loaded electrodes). These
currents reversed around ECl and were
abolished by TTX (1 µM; n = 3) (Fig.
6A) and picrotoxin (50 µM; n = 4; data not shown), suggesting
action potential-dependent activity of GABA-releasing neurons within
the preparation.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 6.
Depression of sIPSCs by activation of µ opioid
receptors. A, sIPSCs in a single GP neuron recorded at a
holding potential of 50 mV in the presence of CNQX (10 µM) and DL-AP-5 (100 µM). Bath
application of met-enkephalin (30 µM) suppressed the
frequency and amplitude of sIPSCs. This effect was replicated by the µ opioid receptor agonist DAMGO (1 µM), whereas the opioid receptor agonist DPDPE (1 µM) was without effect.
sIPSCs were blocked by TTX (1 µM). B,
Cumulative frequency distributions of sIPSCs before and after the
addition of met-enkephalin (p < 0.05)
(i), DAMGO (p < 0.05)
(ii), and DPDPE (non significant) (iii).
Data were collected over a period of 120 sec. Same cell as
A.
|
|
Met-enkephalin (30 µM) caused a significant reversible
depression in frequency of sIPSCs in 10 of 11 cells (five I type, five II type cells; p < 0.05), an effect that was mimicked
by DAMGO (1 µM; 9 of 11 cells; five I type and four II
type neurons). However, DPDPE 1 µM had no effect on the
frequency of sIPSCs in all nine cells tested (three type I, six type II
cells) (Fig. 6).
These results suggest that presynaptic µ opioid receptors modulate
GABA release from axon terminals arising from spontaneously firing
neurons within the preparation and that presynaptic receptors are
located on the terminals of axons arising from quiescent, possibly,
type II GP neurons.
 |
DISCUSSION |
GP neuronal subtypes
In this study, two major subtypes of GP neuron have been
characterized electrophysiologically. These neurons are similar but not
identical to those reported previously (Nambu and Llinás, 1994 ,
1997 ). Therefore, they were provisionally classed as type I and type II
GP neurons in accordance with these previous studies.
Type I neurons (34% of total recordings) showed no evidence of inward
rectification or anodal break depolarizations. These cells exhibited a
low input resistance, consistent with type I neurons of Nambu and
Llinás (1994) . However, they differed from those reported
previously because they were spontaneously active at resting membrane
potentials and showed shorter action potential and AHP durations (Nambu
and Llinás, 1994 ).
Sixty-six percent of cells recorded in the GP showed marked anomalous
inward rectification on hyperpolarization
(Ih) [this current was readily blocked
by 2 mM cesium and 100 µM ZD 7288 (our
unpublished observations)] and anodal break depolarizations often
accompanied by action potential firing. These neurons also had a
relatively high input resistance and were either quiescent or firing
spontaneous action potentials at a tonic rate. These cells probably
correspond to the type II cells described by Nambu and Llinás
(1994) , which exhibited rebound depolarizations and a high input resistance.
The discrepancies in neuronal characteristics between the present study
and that of Nambu and Llinás (1994) may arise from differences in
species (rats vs guinea pigs), slice preparation (300-µm-thick slices
vs 600-1000 µm strips) or recording technique (whole-cell vs sharp microelectrode).
Presynaptic inhibition of striatopallidal
GABAA IPSCs
Met-enkephalin and the µ opioid receptor agonist DAMGO depressed
the GABAA receptor-mediated IPSCs evoked by stimulation
within the striatum. Met-enkephalin also induced an increase in
paired-pulse facilitation (an effect blocked by the selective µ opioid receptor antagonist CTOP) and reduced the frequency of mIPSCs.
The opioid receptor agonist DPDPE had no effect on striatal evoked
IPSCs. These results indicate that enkephalin, acting
at presynaptic µ but not opioid receptors, may reduce GABA
release from striatopallidal terminals. This is in agreement with
binding and immunohistochemical studies, which have demonstrated the
presynaptic location of µ opioid receptors on striatopallidal
terminals (Abou Khalil et al., 1984 ; Olive et al., 1997 ) and suggests a
possible autoinhibitory role for endogenous enkephalin released from
striatopallidal terminals.
Presynaptic inhibition of pallidopallidal GABAA IPSCs
in the GP
IPSCs evoked by stimulation within the GP were depressed by the
activation of both µ and opioid receptors. The µ opioid receptor agonist DAMGO inhibited locally evoked IPSCs and reduced the
frequency of mIPSCs, confirming a presynaptic locus of action. This
could be caused by an action on striatopallidal terminals or
intrinsic GP terminals. An indication of whether these terminals arose
from striatal neurons or intrinsic GP cells was given by the study of
sIPSCs, which were both TTX- and picrotoxin-sensitive, implying
dependence on spontaneously firing GABA-containing neurons whose cell
bodies have been preserved in the preparation. Application of either
met-enkephalin or DAMGO reduced the frequency of sIPSCs. Because
postsynaptic responses to opioid receptor agonists were rarely
observed, this reduction in sIPSCs is most likely to be a result of the
presynaptic µ opioid receptor modulation of GABA release. Because the
major GABA input to the GP arises from the striatum and the majority of
these neurons are quiescent, it is likely that this modulation is on
presynaptic terminals of spontaneously firing GP cells. One possible
candidate cell type is the type I GP neuron.
DPDPE also reduced IPSCs evoked by local GP stimulation and reduced the
frequency of mIPSCs, indicative of a presynaptic location of receptors in the GP. The modulation of GABA release by opioid
receptors from rat slices of GP has been reported previously (Dewar et
al., 1987 ), although the precise location of this presynaptic modulation could not be determined. In contrast, DPDPE had no effect on
sIPSCs. Therefore, the presynaptic receptors may well be located on
the presynaptic terminals of quiescent GP neurons (possibly type II) or
another nonstriatal source of GABA input to the GP.
Despite the evidence for pallidopallidal GABA terminals expressing
functional presynaptic µ and opioid receptors, this has yet to be
corroborated by anatomical studies. A number of studies have indicated
scattered cells in the GP, each expressing high levels of µ opioid
receptor mRNA or moderate levels of mRNA (Delfs et al., 1994 ;
Mansour et al., 1994 ). mRNA for both µ and opioid receptors have
also been found in scattered cells in the human GPe (Peckys and
Landwehrmeyer, 1999 ). Therefore, opioid receptor protein transport from
GP somata to presynaptic terminals remains a possibility.
Postsynaptic effects of opioid receptor activation in the GP
Immunohistochemical studies of postsynaptic opioid receptor
localization are primarily in agreement with the in situ
hybridization data (Bausch et al., 1995 ; Ding et al., 1996 ; Olive et
al., 1997 ). In addition, postsynaptic DOR1 (antibody to opioid
receptors) immunostaining has been reported to be present on
pallidostriatal feedback neurons (Olive et al., 1997 ). These neurons
may be equivalent to the discrete population of GP cells, which
selectively innervate subpopulations of interneurons in the striatum
(Bevan et al., 1998 ).
We did not observe functional postsynaptic µ and receptors in GP
neurons because changes in holding current on met-enkephalin application were rare. A small proportion of cells did show changes in
mIPSC amplitude on application of DAMGO (one of seven cells) or DPDPE
(one of four cells), indicative of postsynaptic receptors. However, we
were unable to correlate these changes with a specific neuronal
population. It may well be that there is a small population of GP
neurons, as yet unidentified, which possess functional postsynaptic opioid receptors.
The lack of a measurable functional change per se does not preclude the
fact that postsynaptic opioid receptors may be linked to other effector
mechanisms other than those that alter membrane conductance or
potential. Postsynaptic opioid receptor activation may produce
long-term changes in GP cell physiology via alterations in gene
expression. Indeed, systemic morphine administration has been shown to
increase the expression of transcription factors, such as Fos, in the
striatum and nucleus accumbens (Bontempi and Sharp, 1997 ).
Implications for opioid modulation of GABA transmission in the GP
and relation to movement disorders
This study supports the notion that endogenous enkephalin acts at
both µ presynaptic opioid receptors on striatopallidal terminals and µ and presynaptic opioid receptors on pallidopallidal terminals to modulate the release of GABA. Thus, enkephalin appears to regulate inhibitory synaptic activity in the GP and may guard against total repression of GP GABA output. The classical model predicts that dopamine depletion leads to this excessive striatopallidal activity, inhibition of GP neurons, and a reduction in GP GABA output. However, a
number of studies have indicated that, in experimental parkinsonism, the GP shows increased excitatory responses and increases in burst firing, which may indeed enhance GABA release from GP neurons (Tremblay
et al., 1989 ; Filion and Tremblay, 1991 ; Chesselet and Delfs, 1996 ).
This apparent paradoxical increase in GP neuronal activity may be a
direct result of an increase in STN excitatory input (Chesselet and
Delfs, 1996 ) or alternatively caused by the overriding adaptive
mechanism of enkephalin reducing GABA release from both striatopallidal
terminals and terminals of intrinsic GP axon collaterals. In keeping
with this function of enkephalin, levels of mRNA and protein are
increased in the striatum of parkinsonism animals (Augood et al., 1989 ;
Asselin et al., 1994 ), although a small proportion of pallidal neurons
show increased mRNA for enkephalin after 6-hydroxydopamine lesions
(Marshall et al., 1999 ).
Presynaptic receptors appear to be preferentially located on the
terminals of quiescent cells, possibly type II neurons. In contrast, µ opioid receptors appear to play a role in the modulation of GABA
release on pallidopallidal terminals of tonically firing type I or type
II GP neurons. The overall physiological function of both these
presynaptic opioid receptors will be dependent on the degree of STN
excitation, the extent of GP neuronal interconnectivity, and the
association between quiescent and tonically firing neurons, which at
present is unknown.
 |
FOOTNOTES |
Received Jan. 20, 1999; revised April 5, 1999; accepted April 7, 1999.
This work was supported by The Wellcome Trust Grant 050196/Z/97/Z. We
thank Drs. Lacey and Wigmore for helpful discussion and appraisal of
this manuscript.
Correspondence should be addressed to Ian M. Stanford, The Department
of Pharmacology, Division of Neuroscience, The Medical School, The
University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
 |
REFERENCES |
-
Abou Khalil B,
Young AB,
Penney JB
(1984)
Evidence for the presynaptic localization of opiate binding sites on striatal efferent fibers.
Brain Res
323:21-29[Web of Science][Medline].
-
Alexander GE,
Crutcher MD
(1990)
Functional architecture of basal ganglia circuits: neural substrates of parallel processing.
Trends Neurosci
13:266-271[Web of Science][Medline].
-
Asselin MC,
Soghomonian JJ,
Cote P,
Parent A
(1994)
Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys.
NeuroReport
5:2137-2140[Web of Science][Medline].
-
Augood SJ,
Emson P,
Mitchell IJ,
Boyce S,
Clarke CE,
Crossman AR
(1989)
Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys.
Mol Brain Res
6:85-92[Medline].
-
Austin MC,
Kalivas PW
(1990)
Enkephalinergic and GABAergic modulation of motor activity in the ventral pallidum.
J Pharm Exp Ther
252:1370-1377[Abstract/Free Full Text].
-
Bausch SB,
Patterson TA,
Appleyard SM,
Chavkin C
(1995)
Immunocytochemical localization of
opioid receptors in the mouse brain.
J Chem Neuroanat
8:175-189[Web of Science][Medline]. -
Bevan MD,
Booth PAC,
Eaton SA,
Bolam JP
(1998)
Selective innervation of neostriatal interneurons by a subclass of neuron in the globus pallidus.
J Neurosci
18:9438-9452[Abstract/Free Full Text].
-
Bolam JP,
Smith Y
(1992)
The striatum and globus pallidus send convergent synaptic inputs onto single cells in the entopeduncular nucleus of the rat: a double anterograde labelling study combined with post-embedding immunocytochemistry for GABA.
J Comp Neurol
321:456-476[Web of Science][Medline].
-
Bontempi B,
Sharp FR
(1997)
Systemic morphine-induced Fos protein in the rat striatum and nucleus accumbens is regulated by µ opioid receptors in the substantia nigra and ventral tegmental area.
J Neurosci
17:8596-8612[Abstract/Free Full Text].
-
Chesselet MF,
Delfs JM
(1996)
Basal ganglia and movement disorders: an update.
Trends Neurosci
19:417-422[Web of Science][Medline].
-
Cornwall J,
Cooper JD,
Phillipson OT
(1990)
Projections to the rostral reticular thalamic nucleus in the rat.
Exp Brain Res
80:157-171[Web of Science][Medline].
-
Davies CH,
Davies SN,
Collingridge GL
(1990)
Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus.
J Physiol (Lond)
424:513-532[Abstract/Free Full Text].
-
Delfs JM,
Kong H,
Mester A,
Chen Y,
Yu L,
Reisine T,
Chesselet MF
(1994)
Expression of µ opioid receptor mRNA in rat brain: in situ hybridization study at the single cell level.
J Comp Neurol
345:46-68[Web of Science][Medline].
-
DeLong MR
(1971)
Activity of pallidal neurons during movement.
J Neurophysiol
34:414-427[Free Full Text].
-
DeLong MR
(1990)
Primate models of movement disorders of basal ganglia origin.
Trends Neurosci
13:281-285[Web of Science][Medline].
-
Dewar D,
Jenner P,
Marsden CD
(1987)
Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of the rat globus pallidus.
Biochem Pharmacol
36:1741-1747[Web of Science][Medline].
-
Ding YQ,
Kaneko T,
Nomura S,
Mizuno N
(1996)
Immunohistochemical localization of µ-opioid receptors in the central nervous system of the rat.
J Comp Neurol
367:375-402[Web of Science][Medline].
-
Filion M,
Tremblay L
(1991)
Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.
Brain Res
547:142-151[Web of Science][Medline].
-
Frayne SE,
Mitchell IJ,
Sharpe PT,
Sambrook MA,
Crossman AR
(1991)
Distribution of enkephalin gene expression in the striatum of the parkinsonian primate: implications for dopamine agonist induced dyskinesia.
Mol Pharmacol
1:53-58[Abstract/Free Full Text].
-
Gandia JA,
Delasheras S,
Garcia M,
Giménez-Amaya JM
(1993)
Afferent projections to the reticular thalamic nucleus from the globus pallidus and substantia nigra of the rat.
Brain Res Bull
32:351-358[Web of Science][Medline].
-
Gerfen CR,
Young WS
(1988)
Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study.
Brain Res
460:161-167[Web of Science][Medline].
-
Gerfen CR,
Engber TM,
Mahan LC,
Susel Z,
Chase TN,
Monsma FJJ,
Sibley DR
(1990)
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
Science
250:1429-1432[Abstract/Free Full Text].
-
Hazrati LN,
Parent A
(1991)
Projection from the external pallidum to the reticular thalamic nucleus in the squirrel monkey.
Brain Res
550:142-146[Web of Science][Medline].
-
Hazrati LN,
Parent A
(1992)
The striatopallidal projection displays a high degree of anatomical specificity in the primate.
Brain Res
592:213-227[Web of Science][Medline].
-
Hontanilla B,
Parent A,
Giménez-Amaya JM
(1994)
Compartmental distribution of parvalbumin and calbindin D-28k in rat globus pallidus.
NeuroReport
5:2269-2272[Web of Science][Medline].
-
Kincaid AE,
Penny Jr JB,
Young AB,
Neumans SW
(1991)
Evidence for a projection from the globus pallidus to entopeduncular nucleus in the rat.
Neurosci Lett
128:121-125[Web of Science][Medline].
-
Kita H,
Kitai ST
(1994)
The morphology of globus pallidus projection neurons in the rat: an intracellular staining study.
Brain Res
636:308-319[Web of Science][Medline].
-
Lavoie B,
Parent A,
Bedard PJ
(1991)
Effects of dopamine degeneration on striatal peptide expression in parkinsonian monkeys.
Can J Neurol Sci
18:373-375[Web of Science][Medline].
-
Maneuf YP,
Mitchell IJ,
Crossman AR,
Brotchie JM
(1994)
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.
Exp Neurol
125:65-71[Web of Science][Medline].
-
Mansour A,
Fox CA,
Burke S,
Meng F,
Thompson RC,
Akil H,
Watson SJ
(1994)
µ,
, and opioid receptor mRNA expression in the rat CNS: an in situ hybridization study.
J Comp Neurol
350:412-438[Web of Science][Medline]. -
Mansour A,
Fox CA,
Akil H,
Watson SJ
(1995)
Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications.
Trends Neurosci
18:22-29[Web of Science][Medline].
-
Marshall JF, Hoover BR, Schiller J 1999 Enkephalin-expressing
globus pallidus neurons: characteristics and mRNA regulation after
nigrostriatal injury. Mov Disord [Abstract], in press.
-
Nambu A,
Llinás R
(1994)
Electrophysiology of globus pallidus neurons in vitro.
J Neurophysiol
72:1127-1139[Abstract/Free Full Text].
-
Nambu A,
Llinás R
(1997)
Morphology of globus pallidus neurons: its correlation with electrophysiology in guinea pig brain slices.
J Comp Neurol
377:85-94[Web of Science][Medline].
-
Napier TC
(1992)
Dopamine receptors in the ventral pallidum regulate circling induced by opioids injected into the ventral pallidum.
Neuropharmacology
31:1127-1136[Web of Science][Medline].
-
Obeso JA,
Rodriguez MC,
DeLong MR
(1997)
Basal ganglia pathophysiology: a critical review.
Adv Neurol
74:3-18[Web of Science][Medline].
-
Olive MF,
Anton B,
Micevych P,
Evans CJ,
Maidment NT
(1997)
Presynaptic versus postsynaptic localization of µ and
opioid receptors in dorsal and ventral striatopallidal pathways.
J Neurosci
17:7471-7479[Abstract/Free Full Text]. -
Parent A
(1990)
Extrinsic connections of the basal ganglia.
Trends Neurosci
13:254-259[Web of Science][Medline].
-
Parent A,
Hazrati L-N
(1995)
Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry.
Brain Res Rev
20:128-154[Medline].
-
Peckys D,
Landwehrmeyer GB
(1999)
Expression of µ,
, and opioid receptor messenger RNA in the human CNS: a 35P in situ hybridization study.
Neuroscience
88:1093-1135[Web of Science][Medline]. -
Smith Y,
Bolam JP
(1989)
Neurons of the substantia nigra reticulata receive a dense GABA-containing input from the globus pallidus in the rat.
Brain Res
493:160-167[Web of Science][Medline].
-
Smith Y,
Bolam JP,
Von Krosigk M
(1990)
Topographical and synaptic organisation of GABA containing pallidosubthalamic projection in the rat.
Eur J Neurosci
2:500-511[Web of Science][Medline].
-
Stuart GJ,
Dodt HU,
Sakmann B
(1993)
Patch-clamp recordings from the soma and dendrites of neurons in brain slices using infrared video microscopy.
Pflügers Arch
423:511-518[Web of Science][Medline].
-
Travagli RA,
Williams JT
(1996)
Endogenous monoamines inhibit glutamate transmission in the spinal cord of the guinea-pig.
J Physiol (Lond)
491:177-185[Abstract/Free Full Text].
-
Tremblay L,
Filion M,
Bedard PJ
(1989)
Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism.
Brain Res
498:17-33[Web of Science][Medline].
-
Wilson W,
Phelan KD
(1982)
Dual topographic representation of neostriatum in the globus pallidus of rats.
Brain Res
243:354-359[Web of Science][Medline].
Copyright © 1999 Society for Neuroscience 0270-6474/99/19124796-08$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
M. Rav-Acha, H. Bergman, and Y. Yarom
Pre- and Postsynaptic Serotoninergic Excitation of Globus Pallidus Neurons
J Neurophysiol,
August 1, 2008;
100(2):
1053 - 1066.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-H. Kang-Park, B. L. Kieffer, A. J. Roberts, G. R. Siggins, and S. D. Moore
Presynaptic {delta} Opioid Receptors Regulate Ethanol Actions in Central Amygdala
J. Pharmacol. Exp. Ther.,
February 1, 2007;
320(2):
917 - 925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kita, S. Chiken, Y. Tachibana, and A. Nambu
Origins of GABA(A) and GABA(B) receptor-mediated responses of globus pallidus induced after stimulation of the putamen in the monkey.
J. Neurosci.,
June 14, 2006;
26(24):
6554 - 6562.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Magill, A. Pogosyan, A. Sharott, J. Csicsvari, J. P. Bolam, and P. Brown
Changes in functional connectivity within the rat striatopallidal axis during global brain activation in vivo.
J. Neurosci.,
June 7, 2006;
26(23):
6318 - 6329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.-M. Shin, M. Masuda, M. Miura, H. Sano, T. Shirasawa, W.-J. Song, K. Kobayashi, and T. Aosaki
Dopamine D4 Receptor-Induced Postsynaptic Inhibition of GABAergic Currents in Mouse Globus Pallidus Neurons
J. Neurosci.,
December 17, 2003;
23(37):
11662 - 11672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. M. Stanford
Independent Neuronal Oscillators of the Rat Globus Pallidus
J Neurophysiol,
March 1, 2003;
89(3):
1713 - 1717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. V. Poisik, G. Mannaioni, S. Traynelis, Y. Smith, and P. J. Conn
Distinct Functional Roles of the Metabotropic Glutamate Receptors 1 and 5 in the Rat Globus Pallidus
J. Neurosci.,
January 1, 2003;
23(1):
122 - 130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-Z. Shen and S. W Johnson
Presynaptic modulation of synaptic transmission by opioid receptor in rat subthalamic nucleus in vitro
J. Physiol.,
May 15, 2002;
541(1):
219 - 230.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Terman, J. E. Rubin, A. C. Yew, and C. J. Wilson
Activity Patterns in a Model for the Subthalamopallidal Network of the Basal Ganglia
J. Neurosci.,
April 1, 2002;
22(7):
2963 - 2976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Melis, R. Camarini, M. A. Ungless, and A. Bonci
Long-Lasting Potentiation of GABAergic Synapses in Dopamine Neurons after a Single In Vivo Ethanol Exposure
J. Neurosci.,
March 15, 2002;
22(6):
2074 - 2082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shindou, A. Mori, H. Kase, and M. Ichimura
Adenosine A2A receptor enhances GABAA-mediated IPSCs in the rat globus pallidus
J. Physiol.,
April 15, 2001;
532(2):
423 - 434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Williams, M. J. Christie, and O. Manzoni
Cellular and Synaptic Adaptations Mediating Opioid Dependence
Physiol Rev,
January 1, 2001;
81(1):
299 - 343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A J Cooper and I M Stanford
Electrophysiological and morphological characteristics of three subtypes of rat globus pallidus neurone in vitro
J. Physiol.,
September 1, 2000;
527(2):
291 - 304.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Santoro, S. Chen, A. Luthi, P. Pavlidis, G. P. Shumyatsky, G. R. Tibbs, and S. A. Siegelbaum
Molecular and Functional Heterogeneity of Hyperpolarization-Activated Pacemaker Channels in the Mouse CNS
J. Neurosci.,
July 15, 2000;
20(14):
5264 - 5275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ogura and H. Kita
Dynorphin Exerts Both Postsynaptic and Presynaptic Effects in the Globus Pallidus of the Rat
J Neurophysiol,
June 1, 2000;
83(6):
3366 - 3376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Magill, J. P. Bolam, and M. D. Bevan
Relationship of Activity in the Subthalamic Nucleus-Globus Pallidus Network to Cortical Electroencephalogram
J. Neurosci.,
January 15, 2000;
20(2):
820 - 833.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|